Actuate Therapeutics (NASDAQ:ACTU) Given “Buy” Rating at HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU)‘s stock had its “buy” rating restated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, MarketBeat Ratings reports.

ACTU has been the topic of a number of other research reports. Rodman & Renshaw started coverage on Actuate Therapeutics in a report on Thursday, July 30th. They issued a “buy” rating and a $6.00 target price on the stock. Wall Street Zen cut shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a report on Wednesday, June 24th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Actuate Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $13.67.

Actuate Therapeutics Price Performance

ACTU stock opened at $0.99 on Tuesday. The stock has a market capitalization of $23.69 million, a price-to-earnings ratio of -1.14 and a beta of 0.78. The business’s fifty day moving average price is $1.47 and its two-hundred day moving average price is $2.44. Actuate Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $9.22.

Actuate Therapeutics (NASDAQ:ACTU) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. Research analysts expect that Actuate Therapeutics will post -0.86 EPS for the current year.

Institutional Trading of Actuate Therapeutics

Institutional investors have recently modified their holdings of the company. Palogic Value Management L.P. purchased a new position in Actuate Therapeutics during the 2nd quarter valued at about $153,000. ABS Investment Management LLC bought a new stake in shares of Actuate Therapeutics in the 2nd quarter worth approximately $111,975,000. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Actuate Therapeutics during the second quarter valued at approximately $28,000. Texas Capital Bank Wealth Management Services Inc bought a new position in shares of Actuate Therapeutics during the second quarter valued at approximately $157,000. Finally, BlackRock Inc. purchased a new stake in Actuate Therapeutics in the second quarter worth $138,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.